Molecular Therapeutics for Anaplastic Gliomas

间变性胶质瘤的分子治疗

基本信息

项目摘要

In spite of over thirty years of effort, the prognosis for patients afflicted with malignant gliomas remains dismal. It is the purpose of this Brain Cancer SPORE to have a positive impact on this unacceptable situation by translating the laboratory-based efforts of five groups of scientists into clinical protocols that address the needs for more effective treatments. The themes that will be investigated in this SPORE include: Pathogenesis, Anti-Invasion Strategies, Glioma-Host Interactions, Viral and Gene Therapy, and Anti-Angiogenesis Strategies. Five research projects are proposed, each of which has a translational component that has or is expected to lead to a clinical research protocol. These include: 1) "The role of Human Cytomegalovirus in Human Malignant Glioma Pathogenesis" which will examine an intriguing finding that suggests that cytomegalovirus promotes the development and progression of gliomas; 2) "Interferon-Mediated Suppression of MMP-9 Gene Expression and Function in Gliomas" which will examine the role of cytokines and signal transduction pathways in regulating secretion of a pro-invasive enzyme; 3) "Ion Channels and Transporters as Novel, Glioma-specific Targets", which will examine how abnormal functioning of glioma ion channels can be potentially manipulated to develop new treatment modalities, 4) "Viral and Molecular Chemotherapy of Malignant CNS Tumors", which will utilize the extensive expertise in virology available at UAB to development new gene and viral vector therapies for gliomas, and 5) "The Role of TSP-1 and -2 in the Biology of Gliomas", which will investigate how to utilize fragments of the protein thrombospondin as anti-angiogenic agents. These projects will be supported by Four Cores: 1) Human Brain Tumor Tissue, 2) Clinical Trials; 3) Brain Tumor Animal Core Facility; and 4) Biostatistics. In addition, the SPORE will have a Career Development Program directed at developing the careers of young investigators in brain tumor translational research and a Developmental/Pilot Research Program. This SPORE has strong institutional commitments from both the University and its Cancer Center, and we fully expect to develop active collaborative interactions with both our institutional SPOREs as well as with other SPOREs nationally.
尽管经过三十多年的努力,恶性神经胶质瘤患者的预后仍然令人沮丧。这个脑癌孢子的目的是通过将五组科学家基于实验室的努力转化为临床方案,以解决更有效治疗的需求,对这种不可接受的情况产生积极的影响。在这个孢子将调查的主题包括:发病机制,抗侵袭策略,胶质瘤宿主相互作用,病毒和基因治疗,抗血管生成策略。提出了五个研究项目,每个项目都有一个翻译部分,已经或预计将导致临床研究方案。其中包括:1)“人类巨细胞病毒在人类恶性神经胶质瘤发病机制中的作用”,将研究一项有趣的发现,即巨细胞病毒促进神经胶质瘤的发展和进展; 2)“干扰素介导的神经胶质瘤MMP-9基因表达和功能的抑制”,将研究细胞因子和信号传导途径在调节促侵袭酶分泌中的作用; 3)“离子通道和转运蛋白作为新的神经胶质瘤特异性靶点”,将研究如何潜在地操纵神经胶质瘤离子通道的异常功能以开发新的治疗模式,4)“恶性CNS肿瘤的病毒和分子化疗”,将利用UAB在病毒学方面的广泛专业知识开发用于神经胶质瘤的新基因和病毒载体疗法,和5)“TSP-1和TSP-2在神经胶质瘤生物学中的作用”,其将研究如何利用血小板反应蛋白的片段作为抗血管生成剂。这些项目将得到四个核心的支持:1)人类脑肿瘤组织,2)临床试验; 3)脑肿瘤动物核心设施;和4)生物统计学。此外,SPORE将有一个职业发展计划,旨在发展年轻研究人员在脑肿瘤转化研究和发展/试点研究计划中的职业生涯。该SPORE具有来自大学及其癌症中心的强有力的机构承诺,我们完全期望与我们的机构SPORE以及全国其他SPORE开展积极的合作互动。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

G. YANCEY GILLESPIE其他文献

G. YANCEY GILLESPIE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('G. YANCEY GILLESPIE', 18)}}的其他基金

Glioblastoma tumor microenvironmental influence on acquired and inherent cancer therapy resistance.
胶质母细胞瘤肿瘤微环境对获得性和固有的癌症治疗耐药性的影响。
  • 批准号:
    10046398
  • 财政年份:
    2018
  • 资助金额:
    $ 107.3万
  • 项目类别:
A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma.
M032(一种表达 IL-12 的基因工程 HSV-1)在复发/进行性多形性胶质母细胞瘤、间变性星形细胞瘤或胶质肉瘤患者中的 1 期研究。
  • 批准号:
    9455636
  • 财政年份:
    2017
  • 资助金额:
    $ 107.3万
  • 项目类别:
Experimental Glioma Animal Models Core
实验性神经胶质瘤动物模型核心
  • 批准号:
    8299607
  • 财政年份:
    2011
  • 资助金额:
    $ 107.3万
  • 项目类别:
CONTEMPORARY THERAPEUTICS FOR ANAPLASTIC GLIOMAS
间变性胶质瘤的现代治疗方法
  • 批准号:
    8540977
  • 财政年份:
    2011
  • 资助金额:
    $ 107.3万
  • 项目类别:
CONTEMPORARY THERAPEUTICS FOR ANAPLASTIC GLIOMAS
间变性胶质瘤的现代治疗方法
  • 批准号:
    8337752
  • 财政年份:
    2011
  • 资助金额:
    $ 107.3万
  • 项目类别:
CONTEMPORARY THERAPEUTICS FOR ANAPLASTIC GLIOMAS
间变性胶质瘤的现代治疗方法
  • 批准号:
    8147551
  • 财政年份:
    2011
  • 资助金额:
    $ 107.3万
  • 项目类别:
Molecular Therapeutics for Anaplastic Gliomas
间变性胶质瘤的分子治疗
  • 批准号:
    7908624
  • 财政年份:
    2009
  • 资助金额:
    $ 107.3万
  • 项目类别:
Experimental Glioma Animal Models Core
实验性神经胶质瘤动物模型核心
  • 批准号:
    7747240
  • 财政年份:
    2009
  • 资助金额:
    $ 107.3万
  • 项目类别:
Molecular Therapeutics for Anaplastic Gliomas
间变性胶质瘤的分子治疗
  • 批准号:
    7253509
  • 财政年份:
    2002
  • 资助金额:
    $ 107.3万
  • 项目类别:
Molecular Therapeutics for Anaplastic Gliomas
间变性胶质瘤的分子治疗
  • 批准号:
    6772544
  • 财政年份:
    2002
  • 资助金额:
    $ 107.3万
  • 项目类别:

相似海外基金

Development of Novel Lung Cancer Therapy Using Tumor-Specific Angiogenesis Inhibitors and Drug Repositioning
使用肿瘤特异性血管生成抑制剂和药物重新定位开发新型肺癌疗法
  • 批准号:
    21H03019
  • 财政年份:
    2021
  • 资助金额:
    $ 107.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of biomarkers related to drug resistance of angiogenesis inhibitors
血管生成抑制剂耐药性相关生物标志物的开发
  • 批准号:
    20K08542
  • 财政年份:
    2020
  • 资助金额:
    $ 107.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Structural and Functional Studies of Brain Angiogenesis Inhibitors (BAIs/ADGRBs)
脑血管生成抑制剂 (BAIs/ADGRB) 的结构和功能研究
  • 批准号:
    9813883
  • 财政年份:
    2019
  • 资助金额:
    $ 107.3万
  • 项目类别:
Elucidation of proteinuria expression mechanism by angiogenesis inhibitors and research on adverse effect avoidance
血管生成抑制剂蛋白尿表达机制的阐明及不良反应避免的研究
  • 批准号:
    17K08457
  • 财政年份:
    2017
  • 资助金额:
    $ 107.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Evaluation of cardiotoxicity and elucidation of cardiotoxic molecular mechanisms in cancer patients receiving angiogenesis inhibitors
接受血管生成抑制剂的癌症患者的心脏毒性评估和心脏毒性分子机制的阐明
  • 批准号:
    26461102
  • 财政年份:
    2014
  • 资助金额:
    $ 107.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Minimally invasive response evaluation in vivo for the dual therapy of the angiogenesis inhibitors
血管生成抑制剂双重治疗的体内微创疗效评价
  • 批准号:
    23591763
  • 财政年份:
    2011
  • 资助金额:
    $ 107.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
ANGIOGENESIS INHIBITORS IN THE MULTIMODAL TREATMENT OF PEDIATRIC SOLID TUMORS
血管生成抑制剂在小儿实体瘤多模式治疗中的应用
  • 批准号:
    8309814
  • 财政年份:
    2011
  • 资助金额:
    $ 107.3万
  • 项目类别:
Discovery and Investigation of Novel Angiogenesis Inhibitors Among Existing Drugs
现有药物中新型血管生成抑制剂的发现和研究
  • 批准号:
    7351352
  • 财政年份:
    2008
  • 资助金额:
    $ 107.3万
  • 项目类别:
Discovery and Investigation of Novel Angiogenesis Inhibitors Among Existing Drugs
现有药物中新型血管生成抑制剂的发现和研究
  • 批准号:
    8002099
  • 财政年份:
    2008
  • 资助金额:
    $ 107.3万
  • 项目类别:
Discovery and Investigation of Novel Angiogenesis Inhibitors Among Existing Drugs
现有药物中新型血管生成抑制剂的发现和研究
  • 批准号:
    7537218
  • 财政年份:
    2008
  • 资助金额:
    $ 107.3万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了